![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Vitamin E comprises 8 functionally unique isoforms and may be a suitable candidate for the adjuvant treatment of prostate cancer. In this study, we examined the ability of 2 vitamin E isoforms [α-tocotrienol (γ-TT) and δ-tocotrienol (δ-TT)] and 4 synthetic derivatives [γ- and δ-tocotrienol succinate (γ-TS, δ-TS), α-tocopheryl polyethylene glycol succinate (TPGS), and α-tocopheryl polyethylene glycol ether (TPGS-e)] of vitamin E to induce cell death in AR− (DU145 and PC-3) and AR+ (LNCaP) prostate cancer cell lines. Our results show that δ-TT and TPGS-e are the most effective isoform and synthetic derivative, respectively, of all compounds examined. Overall, the results of our study suggest that isoforms and synthetic derivatives of vitamin E have the potency to trigger both caspase-dependent and -independent DNA damage and dominant caspase-independent programmed cell death. The capacity of vitamin E to trigger caspase-independent programmed cell death suggests that it may be useful in the chemotherapy of prostate cancer since it may prevent the tumor resistance commonly associated with the use of classical chemotherapeutic agents that trigger caspase-dependent programmed cell death.
ACKNOWLEDGMENTS
Research was supported by the Cyprus Research Promotion Foundation (grant-KINHTIKOTHTA/0506/06, grant YTEIA/0104/06, and grant SYNERGIA/0505/20).
During the performance of the current study, Dr. Constantina Constantinou, Dr. Konstantinos A. Papas, and John Anthony Hyatt were employed by Yasoo Health, Ltd., and Yasoo Health, Inc., respectively, which market dietary supplements.
C. Constantinou is now with the Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus. P. Vraka is now with the Histopathology Department, Nicosia General Hospital, Nicosia, Cyprus.